Online inquiry

IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3507MR)

This product GTTS-WQ3507MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3507MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14115MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ6920MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ1007MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ1370MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ3855MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ858MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ15455MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ15424MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW